5 Key Takeaways

• 1

  CureSight is a digital amblyopia treatment platform approved for children ages 4 to 9 with specific visual acuity and strabismus criteria.

• 2

  The device uses eye-tracking technology and red-blue glasses to blur the dominant eye's vision, promoting use of the affected eye.

• 3

  Treatment is recommended for at least 6 months, with a standard follow-up every 3 months to monitor progress and adherence.

• 4

  CureSight is contraindicated for patients with light-induced epilepsy and may not be suitable for those with limited attention spans.

• 5

  Insurance coverage for CureSight varies, and NovaSight offers cash-pay options and financial assistance programs for patients.